Immunohistochemical analysis of RTKs expression identified HER3 as a prognostic indicator of gastric cancer

Cancer Science

Volumn 105, Issue 12, 2014, Pages 1591-1600

  Ema, Akira ^a   Yamashita, Keishi ^a   Ushiku, Hideki ^a   Kojo, Ken ^a   Minatani, Naoko ^a   Kikuchi, Mariko ^a   Mieno, Hiroaki ^a   Moriya, Hiromitsu ^a   Hosoda, Kei ^a   Katada, Natsuya ^a   Kikuchi, Shiro ^a   Watanabe, Masahiko ^a  

^a KITASATO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Advanced gastric cancer; HER3; Prognosis; Receptor type tyrosine kinases (RTKs); S 1

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 3; ERBB3 PROTEIN, HUMAN; PROTEIN TYROSINE KINASE;

ADJUVANT CHEMOTHERAPY; AGED; DISEASE FREE SURVIVAL; FEMALE; GENE AMPLIFICATION; GENETICS; HUMAN; MALE; METABOLISM; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PATHOLOGY; PROGNOSIS; STOMACH NEOPLASMS;

AGED; CHEMOTHERAPY, ADJUVANT; DISEASE-FREE SURVIVAL; FEMALE; GENE AMPLIFICATION; HUMANS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; RECEPTOR PROTEIN-TYROSINE KINASES; RECEPTOR, ERBB-3; STOMACH NEOPLASMS;

EID: 84917691322     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/cas.12556     Document Type: Article

References (40)

1. Ferlay J, Shin HR, Bray F et al. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010; 127: 2893-917.
2. Sakuramoto S, Sasako M, Yamaguchi T et al. Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N Engl J Med 2007; 357: 1810-20.
3. Sasako M, Sakuramoto S, Katai H et al. Five-year outcomes of a randomized phase III trial comparing adjuvant chemotherapy with S-1 versus surgery alone in stage II or III gastric cancer. J Clin Oncol 2011; 29: 4387-93.
4. Maurer CA, Friess H, Kretschmann B et al. Increased expression of erbB3 in colorectal cancer is associated with concomitant increase in the level of erbB2. Hum Pathol 1998; 29: 771-7.
5. Lee JC, Wang ST, Chow NH et al. Investigation of the prognostic value of coexpressed erbB family members for the survival of colorectal cancer patients after curative surgery. Eur J Cancer 2002; 38: 1065-71.
6. Japanese Gastric Cancer Association. Japanese gastric cancer treatment guidelines 2010 (ver. 3). Gastric Cancer 2011; 14: 113-23.
7. Ema A, Yamashita K, Sakuramoto S et al. Lymph node ratio is a critical prognostic predictor in gastric cancer treated with S-1 chemotherapy. Gastric Cancer 2014a; 17: 67-75.
8. Vergara-Lluri ME, Moatamed NA, Hong E et al. High concordance between HercepTest immunohistochemistry and ERBB2 fluorescence in situ hybridization before and after implementation of American Society of Clinical Oncology/College of American Pathology 2007 guidelines. Mod Pathol 2012; 25: 1326-32.
9. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitaitve PCR and the 2(-Delta Delata C(T)) Method. Methods 2001; 25: 402-8.
10. Yasui W, Hata J, Yokozaki H et al. Interaction between epidermal growth factor and its receptor in progression of human gastric carcinoma. Int J Cancer 1988; 41: 211-7.
11. Garcia I, Vizoso F, Martin A et al. Clinical significance of the epidermal growth factor receptor and HER2 receptor in resectable gastric cancer. Ann Surg Oncol 2003; 10: 234-41.
12. Hayashi M, Inokuchi M, Takagi Y et al. High expression of HER3 is associated with a decreased survival in gastric cancer. Clin Cancer Res 2008; 14: 7843-9.
13. Matsubara J, Yamada Y, Nakajima TE et al. Clinical significance of insulin-like growth factor type 1 receptor and epidermal growth factor receptor in patients with advanced gastric cancer. Oncology 2008a; 74: 76-83.
14. Kim MA, Lee HS, Lee HE et al. EGFR in gastric carcinomas: prognostic significance of protein overexpression and high gene copy number. Histopathology 2008; 52: 738-46.
15. Okines A, Cunningham D, Chau I. Targeting the human EGFR family in esophagogastric cancer. Nat Rev Clin Oncol 2011; 8: 492-503.
16. Terashima M, Kitada K, Ochiai A et al. Impact of expression of human epidermal growth factor receptors EGFR and ERBB2 on survival in stage II/III gastric cancer. Clin Cancer Res 2012; 18: 5992-6000.
17. Oh HS, Eom DW, Kang GH et al. Prognostic implications of EGFR and HER-2 alteration assessed by immunohistochemistry and silver in situ hybridization in gastric cancer patients following curative resection. Gastric Cancer 2014; 17: 402-11.
18. Kurokawa Y, Matsuura N, Kawabata R et al. Prognostic impact of major receptor tyrosine kinase expression in gastric cancer. Ann Surg Oncol 2014. doi: 10.1245/s10434-014-3690-x
19. Nagatsuma AK, Aizawa M, Kuwata T et al. Expression profiles of HER2, EGFR, MET and FGFR2 in a large cohort of patients with gastric adenocarcinoma. Gastric Cancer 2014. doi: 10.1007/s10120-014-0360-4
20. Zhang XL, Yang YS, Xu DP et al. Comparative study on overexpression of HER2/neu and HER3 in gastric cancer. World J Surg 2009; 33: 2112-8.
21. Begnami MD, Fukuda E, Fregnani JH et al. Prognostic implications of altered human epidermal growth factor receptors (HERs) in gastric carcinomas: HER2 and HER3 are predictors of poor outcome. J Clin Oncol 2011; 29: 3030-6.
22. Ocana A, Vera-Badillo F, Seruga B et al. HER3 overexpression and survival in solid tumors: a meta-analysis. J Natl Cancer Inst 2013; 105: 266-73.
23. Wu X, Chen Y, Li G et al. Her3 is associated with poor survival of gastric adenocarcinoma: Her3 promotes proliferation, survival and migration of human gastric cancer mediated by PI3K/AKT signaling pathway. Med Oncol 2014; 31: 903.
24. Matsubara J, Yamada Y, Hirashima Y et al. Impact of insulin-like growth factor type 1 receptor, epidermal growth factor receptor, and HER2 expressions on outcomes of patients with gastric cancer. Clin Cancer Res 2008b; 14: 3022-9.
25. Ge J, Chen Z, Wu S et al. Expression levels of insulin-like growth factor-1 and multidrug resistance-associated protein-1 indicate poor prognosis in patients with gastric cancer. Digestion 2009; 80: 148-58.
26. Yuan WJ, Ge J, Chen ZK et al. Over-expression of EphA2 and EphrinA-1 in human gastric adenocarcinoma and its prognostic value for postoperative patients. Dig Dis Sci 2008; 54: 2410-7.
27. Yuan W, Chen Z, Chen Z et al. Silencing of EphA2 inhibits invasion of human gastric cancer SGC-7901 cells in vitro and in vivo. Neoplasma 2012; 59: 105-13.
28. Hou F, Yuan W, Huang J et al. Overexpression of EphA2 correlates with epithelial-mesenchymal transition-related proteins in gastric cancer and their prognostic importance for postoperative patients. Med Oncol 2012; 29: 2691-700.
29. Miyazaki K, Inokuchi M, Takagi Y et al. EphA4 is a prognostic factor in gastric cancer. BMC Clin Pathol 2013; 13: 19.
30. Ema A, Waraya M, Yamashita K et al. Identification of EGFR expression status association with metastatic lymph node density (ND) by expression microarray analysis of advanced gastric cancer. Cancer Med 2014b. doi: 10.1002/cam4.311
31. Sithanandam G, Anderson LM. The ERBB3 receptor in cancer and cancer gene therapy. Cancer Gene Ther 2008; 15: 413-48.
32. Yoshioka T, Nishikawa Y, Ito R et al. Significance of integrin alphavbeta5 and erbB3 in enhanced cell migration and liver metastasis of colon carcinomas stimulated by hepatocyte-derived heregulin. Cancer Sci 2010; 101: 2011-8.
33. Kobayashi M, Nagata S, Iwasaki T et al. Dedifferentiation of adenocarcinomas by activation of phosphatidylinositol 3-kinase. Proc Natl Acad Sci USA 1999; 96: 4874-9.
34. Kobayashi M, Iwamatsu A, Shinohara-Kanda A et al. Activation of ErbB3-PI3-kinase pathway is correlated with malignant phenotypes of adenocarcinomas. Oncogene 2003; 22: 1294-301.
35. Yamashita K, Sakuramoto S, Watanabe M. Genomic and epigenetic profiles of gastric cancer: potential diagnostic and therapeutic applications. Surg Today 2011; 41: 24-38.
36. Kunii K, Davis L, Gorenstein J et al. FGFR2-amplified gastric cancer cell lines require FGFR2 and Erbb3 signaling for growth and survival. Cancer Res 2008; 68: 2340-8.
37. Yashiro M, Shinto O, Nakamura K et al. Synergistic antitumor effects of FGFR2 inhibitor with 5-fluorouracil on scirrhous gastric carcinoma. Int J Cancer 2010; 126: 1004-16.
38. Jaiswal BS, Kljavin NM, Stawiski EW et al. Oncogenic ERBB3 mutations in human cancers. Cancer Cell 2013; 23: 603-17.
39. Jung EJ, Jung EJ, Min SY et al. Fibroblast growth factor receptor 2 gene amplification status and its clinicopathologic significance in gastric carcinoma. Hum Pathol 2012; 43: 1559-66.
40. Su X, Zhan P, Gavine PR et al. FGFR2 amplification has prognostic significance in gastric cancer: results from a large international multicentre study. Br J Cancer 2014; 110: 967-75.